With liver ailments on the rise, and obesity a key driver, understanding the treatment options available is critical.

Arrowhead Pharmaceuticals, Inc. today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be ...

GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, ...

In 2025, a new breed of entrepreneurial disruptors is set to reshape industries and redefine success on their own term ...

College basketball stars Olivia Miles and Ta'Niyah Latson made decisions this week, as the NCAA transfer portal continues ...

Gor Mahia coach Sinisa Mihic has sent a rallying message to the club's management with regards to the transfer window after ...

Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...

Every patient in the trial has met the primary safety endpoint, confirmed through PET imaging showing precise retention of the therapeutic Yttrium-90 isotope at the injection site—with no observed ...

Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

Adoption allows ICON to take full advantage of the Medidata "Data Experience," leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts NEW YORK, March 20, 2025 ...

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

UD students interested in advanced health care professions will have an additional pathway, starting with the entering undergraduate class in fall 2025. UD’s Doctor of Physical Therapy and Master of ...